Replies to post #366370 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

He is not correct. He said the SAP and Endpoints were revised "Post Hoc", after the DCVax-L trial data was unblinded.

That is simply not true. I think it was a deliberate lie to help some Shorts & MMs trigger some Stop Losses down to $1.31 per share.

Since his tweet, about 2 million NWBO have traded. But, it will not be enough to help most of the Shorts & MMs.

Most investors who own NWBO shares, know about the revised SAP & new Endpoints timeline & the Buy-in process with the 4 regulatory authorities.

Unfortunately, there were a few NWBO who have fallen victim to this FUD attack.

[longfellow95]

Endpoints are changed in numerous trials all the time.
If you do it before unblind and get regulator approval to do so, it's not a major issue. A regulator should not approve an endpoint change, if they think it is not warranted or justifiable given all the prevailing circumstances.
So nothing has changed. We know that at least two of the three major regulators have green-lighted the new endpoints.